ASSOCIATION OF TYPE 2 DIABETES AMONG REPRODUCTIVE-AGED WOMEN HAVING POLYCYSTIC OVARIAN SYNDROME IN SIALKOT

Q SHAKEEL; S ASHRAF; F NADEEM; K SEHAR; MA BUTT; R ASLAM; MS RASHEED

doi:10.54112/bcsrj.v2024i1.985

Authors

Q SHAKEEL Department of Zoology University of Sialkot, Pakistan
S ASHRAF Department of Zoology University of Sialkot, Pakistan
F NADEEM Department of Zoology University of Sialkot, Pakistan
K SEHAR Department of Zoology University of Sialkot, Pakistan
MA BUTT Department of Zoology University of Sialkot, Pakistan
R ASLAM Department of Zoology University of Sialkot, Pakistan
MS RASHEED Department of Zoology University of Narowal, Narowal Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.985

Keywords:

Diabetes Mellitus, Female, Insulin Resistance, Polycystic Ovary Syndrome, Reproductive Age, Risk Factors

Abstract

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder among women of reproductive age, characterized by elevated androgen levels, ovarian cysts, and symptoms such as irregular menstrual cycles, hirsutism, and acne. PCOS is often associated with insulin resistance, which increases the risk of developing type 2 diabetes mellitus (T2DM). Objective: This study aimed to explore the relationship between PCOS and T2DM in women of reproductive age, focusing on the prevalence of symptoms, risk factors, and potential interventions. Methods: A cross-sectional study was conducted from April to June 2024, involving 100 women aged 18 to 43 at Sardar Begum Hospital and Cheema Family Hospital in Sialkot. Participants were divided equally into PCOS (n=50) and control groups (n=50). Data were collected on demographic and clinical characteristics, including HbA1c levels, using a structured form and laboratory tests. Descriptive statistics, independent samples t-tests, and chi-square tests analyzed the data. Results: The PCOS group exhibited a significantly higher prevalence of irregular menstrual cycles (87%), hirsutism (67%), and acne (40%) compared to the control group. Elevated HbA1c levels were observed in 25% of the PCOS group, with 15% having levels above 6.4%, indicating a heightened risk for T2DM. The mean HbA1c level was significantly higher in the PCOS group (6.2%) compared to the control group (5.5%). Additionally, 60% of women with PCOS reported a family history of diabetes, suggesting a genetic predisposition. Conclusion: Women with PCOS are at a significantly higher risk of developing T2DM. The study highlights the need for early screening and comprehensive management strategies to mitigate these risks. A multidisciplinary approach involving various healthcare professionals is essential for effective intervention and prevention. Further research is necessary to improve the understanding and treatment of these interconnected conditions.

Downloads

Download data is not yet available.

References

Manique MES, Ferreira AMAP. Polycystic ovary syndrome in adolescence: challenges in diagnosis and management. Revista brasileira de ginecologia e obstetricia. 2022;44(04):425-33.

Karkera S, Agard E, Sankova L. The clinical manifestations of polycystic ovary syndrome (PCOS) and the treatment options. European Journal of Biology and Medical Science Research. 2023;11(1):57-91.

Bjekić-Macut J, Vukašin T, Velija-Ašimi Z, Bureković A, Zdravković M, Andrić Z, et al. Polycystic ovary syndrome: a contemporary clinical approach. Current Pharmaceutical Design. 2021;27(36):3812-20.

Louwers YV, Laven JS. Polycystic ovary syndrome (PCOS). Female Reproductive Dysfunction. 2020:1-23.

He F-f, Li Y-m. Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: a review. Journal of ovarian research. 2020;13(1):73.

Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, et al. Resistance to the insulin and elevated level of androgen: A major cause of polycystic ovary syndrome. Frontiers in endocrinology. 2021;12:741764.

Sun Y, Li S, Liu H, Bai H, Hu K, Zhang R, et al. Oxidative stress promotes hyperandrogenism by reducing sex hormone-binding globulin in polycystic ovary syndrome. Fertility and Sterility. 2021;116(6):1641-50.

Teede HJ, Garad RM, Melder A, Norman RJ, Boyle J. Letter to the Editor from Teede:“Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study”. The Journal of Clinical Endocrinology & Metabolism. 2022;107(3):e1321-e2.

Zhu T, Goodarzi MO. Causes and consequences of polycystic ovary syndrome: insights from Mendelian randomization. The Journal of Clinical Endocrinology & Metabolism. 2022;107(3):e899-e911.

Livadas S, Anagnostis P, Bosdou JK, Bantouna D, Paparodis R. Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review. World journal of diabetes. 2022;13(1):5.

Zhao X, Jiang Y, Xi H, Chen L, Feng X. Exploration of the relationship between gut microbiota and polycystic ovary syndrome (PCOS): a review. Geburtshilfe und Frauenheilkunde. 2020;80(02):161-71.

Kent J, Dodson WC, Kunselman A, Pauli J, Stone A, Diamond MP, et al. Gestational weight gain in women with polycystic ovary syndrome: a controlled study. The Journal of Clinical Endocrinology & Metabolism. 2018;103(11):4315-23.